The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. The company ...

The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The US$ ...

As 2024 comes to a close, Leader-Post photojournalist Kayle Neis reflects on five photos that had a big impact on him this year. This exercise is not meant to showcase the “best” photos but ...

"It puts you in a very, very dark place." Gearing will race with the Making Waves Foundation team, crewing the custom-built ocean racing boat Kayle, despite almost walking away from the challenge.

We're building Viridian for living. When you move to Viridian, we want you to have the option to stay here for life." The first phase of homes will be for sale in December 2024. Viridian's ...

Viridian is progressing with two additional phase 3 trials, REVEAL-1 and REVEAL-2, with topline data anticipated in 2026. Viridian Therapeutics has announced topline data from THRIVE-2, (NCT06021054) ...

Viridian Therapeutics is based in Waltham, MA. The company is focused on developing treatments for serious and rare diseases. The company's two most advanced candidates in the clinic (VRDN-001 and ...

10 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...

Credit: mToa55 via Shutterstock. Viridian Therapeutics’s stock has jumped after a Phase III trial of veligrotug met all endpoints and was well tolerated in patients with chronic thyroid eye disease ...